 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > La Jolla Pharmaceutical Company
 |
La Jolla Pharmaceutical Company |
 |
 |
 |
PROFILE |
 |
Development-stage La Jolla Pharmaceutical researches specific therapeutics to treat autoimmune diseases. The firm is developing Toleragens, proprietary therapies that block the abnormal antibody production associated with certain autoimmune disorders without suppressing the entire immune system. Its first drug candidate is LJP 394, a treatment for lupus. The company is exploring the use of Toleragens to fight such other autoimmune disorders as antibody-mediated stroke, deep-vein thrombosis, and Rh hemolytic disease, a fetal condition caused by Rh incompatibility between mother and child. Toleragens might also be useful in xenotransplantation, in which animal organs are transplanted into humans.
COMPETITION |
 |
Alexion Pharmaceuticals, Inc. (ALXN)
Immunex Corporation (IMNX)
InKine Pharmaceutical Company, Inc. (INKP)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (97.9)%
Employees: 78
Revenue per employee: $1,282.05
KEY PEOPLE |
 |
Steven B. Engle
CEO
CONTACT INFO |
 |
6455 Nancy Ridge Dr.
San Diego, CA 92121
US
Phone: 858-452-6600
Fax: 858-452-6893
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |